25 May 2013
Keywords: Genzyme, USA, FDA, Consent decree, Sanofi-Aventis
Article | 25 November 2010
US biotech major Genzyme (NASDAQ: GENZ) said yesterday that it has ended fill/finish operations within its Allston, Massachusetts, plant ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 November 2010
24 May 2013
© 2013 thepharmaletter.com